Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016;128:1688-1700.
Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394:2096-2107.
Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol. 2018;4:849-856.
BLENREP (belantamab mafodotin-blmf) [prescribing information]. GlaxoSmithKline. Approved 2020. Revised August 2020.
Blumenthal GM, Karuri SW, Zhan H, et al. Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses. J Clin Oncol. 2015;33:1008-1014.
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321-3330.
Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J Clin Oncol. 2018;36:2267-2280.
Cancer. Drug Therapy for Multiple Myeloma 2020. Updated August 18, 2020. Accessed October 31, 2019.
https://www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html
Centre for Evidence-Based Medicine (CEBM). Explanation of the 2011 OCEBM Levels of Evidence. Accessed October 31, 2019. https://www.cebm.ox.ac.uk/resources/levels-of-evidence/explanation-of-the-2011-ocebm-levels-of-evidence
Chen EY, Raghunathan V, Prasad V. An overview of cancer drugs approved by the US Food and Drug Administration based on the surrogate end point of response rate. JAMA Intern Med. 2019;179:915-921.
Chng WJ, Dispenzieri A, Chim C-S, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28:269-277.
Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in myeloma myeloma. J Clin Invest. 2019;129:2210-2221.
CTEP Cancer. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Published November 27, 2017. Accessed October 31, 2019. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf
Curigliano G, O’Connor DP, Rosenberg JA, et al. Biosimilars: extrapolation for oncology. Crit Rev Oncol Hematol. 2016;104:131-137.
Dhakal B, Hari PN, Usmani SZ, et al. Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges. Bone Marrow Transplant. 2020. doi:10.1038/s41409-020-01023-w [Epub ahead of print]
Ellimoottil C, Vijan S, Flanigan RC. A primer on clinical trial design. Urol Oncol. 2015;33:116-121.
Fiteni F, Westeel V, Pivot X, et al. Endpoints in cancer clinical trials. J Visc Surg. 2014;151:17-22.
Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266-2275.
Goldberg KB, Blumenthal GM, McKee AE, et al. The FDA Oncology Center of Excellence and precision medicine. Exp Biol Med (Maywood). 2018;243:308-312.
Goswami C, Poonia S, Kumar L, et al. Staging system to predict the risk of relapse in multiple myeloma patients undergoing autologous stem cell transplantation. Front Oncol. 2019;9:633.
Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
Gyawali B, Hey SP, Kesselheim AS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern Med. 2019;179:906-913.
Hickey R, Vouche M, Sze DY, et al. Cancer concepts and principles: primer for the interventional oncologist-part I. J Vasc Interv Radiol. 2013;24:1157-1164.
Ho PM, Peterson PN, Masoudi FA. Evaluating the evidence: is there a rigid hierarchy? Circulation. 2008;118:1675-1684.
Kluetz PG, Chingos DT, Basch EM, et al. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67-73.
Kluetz PG, Slagle A, Papadopoulos EJ, et al. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms. Clinical Cancer Research. 2016;22:1553-1558.
Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443-2448.
Kurtin SE, Bilotti E. Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents. J Adv Pract Oncol. 2013;4:307-321.
Kurtin SE, Taher R. Clinical trials design and drug approval in oncology: a primer for the advanced practitioner in oncology. J Adv Pract Oncol.2020;11:736-751.
Levine BL. Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells. Cancer Gene Ther. 2015;22:79-84.
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21:207-221.
Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7:e370-e380.
Maymone MBC, Gan SD, Bigby M. Evaluating the strength of clinical recommendations in the medical literature: GRADE, SORT, and AGREE. J Invest Dermatol. 2014;134:1-5.
McKee AE, Farrell AT, Pazdur R, et al. The role of the US Food and Drug Administration review process: clinical trial endpoints in oncology. Oncologist. 2010;15(Suppl 1):13-18.
Mikhael J. Treatment options for triple-class refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20:1-7.
National Comprehensive Cancer Network (NCCN). NCCN Guidelines^®. Multiple myeloma version 1.2021. Accessed October 12, 2020. https://www.nccn.org/professionals/physician_gls/
Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47-62.
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: a report from the International Myeloma Working Group. J Clin Oncol. 2015;33:2863-2869.
Premkumar V, Bhutani D, Lentzsch S. Modern treatments and future directions for relapsed/refractory multiple myeloma patients. Clinical Lymphoma Myeloma Leuk. 2020. doi:10.1016/j.clml.2020.06.023 [Epub ahead of print]
Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726-1737.
Raje NS, Yee AJ, Roodman GD. Advances in supportive care for myeloma myeloma. J Natl Compr Canc Netw. 2014;12:502-511.
Richter J, Madduri D, Richard S, et al. Selinexor in relapsed/refractory multiple myeloma. Ther Adv Hematol. 2020;11:2040620720930629.
Santomasso B, Bachier C, Westin J, et al. The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am Soc Clin Oncol Educ Book. 2019;39:433-444.
Simon R, Blumenthal GM, Rothenberg ML, et al. The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther. 2015;97:502-507.
Slaney CY, Wang P, Darcy PK, et al. CARs versus BiTEs: a comparison between T cell-redirection strategies for cancer treatment. Cancer Discov. 2018;8:924-934.
Tai Y-T, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128-3138.
Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: strengths and challenges. Blood Rev. 2018;32:339-347.
Xpovio™(selinexor) [prescribing information]. Karyopharm Therapeutics Inc. Approved 2019. Revised July 2019.
Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol. 2018;11:141.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Disclosures

Disclosure: Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda
Served as a speaker or a member of a speakers bureau for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda

Editor

Sara Fagerlie, PhD, CHCP

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

CE

Novel Therapies for Multiple Myeloma: Highlights for the Oncology Nurse

Authors: Sandra E. Kurtin, PhD, ANP-C, AOCN
CE Released: 10/22/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 10/22/2021

Start Activity

Target Audience and Goal Statement

This activity is intended for oncology nurses and other healthcare providers involved in the care of patients with MM.

The goal of this activity is to improve the knowledge of oncology nurses about novel and emerging therapies used to treat multiple relapsed/refractory (R/R) multiple myeloma (MM) and to improve their skills educating patients about participation in clinical trials.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Risk factors for developing R/R MM
- Potential adverse effects of novel therapies for R/R MM
Have greater competence related to
- Discussing clinical trial participation with patients with R/R MM
Demonstrate greater confidence in their ability to
- Provide education about novel therapies to patients with R/R MM

Disclosures

Faculty

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice
Assistant Professor of Clinical Medicine
Assistant Professor of Nursing
The University of Arizona Cancer Center
Tucson, Arizona

Disclosures

Disclosure: Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda
Served as a speaker or a member of a speakers bureau for: Abbvie; Amgen; AstraZeneca; Genentech; Incyte; Pharmacyclics; Takeda

Editor

Sara Fagerlie, PhD, CHCP

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sara Fagerlie, PhD, CHCP, has disclosed no relevant financial relationships.

CE Reviewer/Nurse Planner

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Disclosure: Stephanie Corder, ND, RN, CHCP, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

Clinical Advances in Multiple Myeloma

From Medscape Education Oncology

Novel Therapies for Multiple Myeloma: Highlights for the Oncology Nurse

Authors: Sandra E. Kurtin, PhD, ANP-C, AOCNFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CE Released: 10/22/2020

Valid for credit through: 10/22/2021

processing....

ADC = antibody-drug conjugate
ADCC = antibody-dependent cell-mediated cytotoxicity
AE = adverse event
ASCT = autologous stem cell transplant
ASTCT = American Society for Transplantation and Cellular Therapy
BCMA = B-cell maturation antigen
BiTE® = bispecific T-cell engager
Bor = bortezomib
Car = carfilzomib
CAR T = chimeric antigen receptor T cell
CBR = clinical benefit rate
CD = cluster of differentiation
CR = complete response
CRS = cytokine release syndrome
CTCAE = Common Terminology Criteria for Adverse Events
CTEP = Cancer Therapy Evaluation Program
Ctrough = trough concentration
Cyclo = cyclophosphamide
Dara = daratumumab
DCEP = dexamethasone, cyclophosphamide, etoposide, cisplatin
del = deletion
Dex = dexamethasone
DFS = disease-free survival
DIC = disseminated intravascular coagulation
DLT = dose-limiting toxicity
DoR = duration of response
Dox = doxorubicin
DT-PACE = dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, etoposide
Elo = elotuzumab
EP = endpoint
Fc = fragment crystallizable
FISH = fluorescent in situ hybridization
Flu = fludarabine
GFR = glomerular filtration rate
GI = gastrointestinal
ICANS = immune effector cell-associated neurologic syndrome
IgG = immunoglobulin G
IL = interleukin
IMiD = immunomodulatory drug
IMP = importin
IMWG = International Myeloma Working Group
Isa = isatuximab
ISS = International Staging System
IV = intravenous
Ixa = ixazomib
LDH = lactate dehydrogenase
Len = lenalidomide
mAb = monoclonal antibody
MM = multiple myeloma
MMAF = monomethyl auristatin F
MR = minor response
MTD = maximum tolerated dose
NA = not available
NCCN = National Comprehensive Cancer Network
NK = natural killer
NPC = nuclear pore complex
ORR = overall response rate
OS = overall survival
PD = progressive disease
PFS = progression-free survival
PI = proteasome inhibitor
PJP = Pneumocystis jirovecii pneumonia
Pom = pomalidomide
PR = partial response
R = randomization
RCT = randomized controlled trial
REMS = Risk Evaluation and Mitigation Strategy
R-ISS = revised International Staging System
RRMM = relapsed/refractory multiple myeloma
SC = subcutaneous
SD = stable disease
SINE = selective inhibitor of nuclear export
t = translocation
thal = thalidomide
TTP = time to progression
ULN = upper limit of normal
VGPR = very good partial response
XPO1 = exportin 1